Kiora Pharmaceuticals

Home
United States
Encinitas, CA
Kiora Pharmaceuticals

Clinical stage biotech company focusing on novel therapeutics for the treatment of retinal diseases Kiora Pharmaceuticals, Inc.

(Kiora) is a clinical development-stage company focusing on novel therapeutics for the treatment of orphan retinal diseases with high unmet need. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision.

01/13/2026

Macular edema can cause blurred or distorted vision — but new research is underway to ﬁnd better solutions to address this condition.

KLARITY-1 — a Phase 2 clinical trial evaluating the safety and effectiveness of KIO-104, an investigational treatment administered via intravitreal injection. The trial explores how KIO-104 may reduce macular swelling and improve vision in patients with macular edema caused by conditions including:

● Diabetic retinopathy

● Non-infectious uveitis

● Retinal vein occlusion

● Cataract surgery

Learn more at: https://bit.ly/KioraHome.

01/07/2026

This is KIO-301: a molecular photoswitch designed to help restore vision in people living with inherited retinal diseases such as retinitis pigmentosa. By turning light signals “on” and “off” within the eye, this investigational therapy aims to restore the ability to sense light where it’s been lost.

It’s science with one goal: turning light into hope.

Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

12/30/2025

At Kiora Pharmaceuticals, our mission is simple yet powerful: to restore sight and renew hope for people living with inherited and acquired retinal diseases. Through science rooted in innovation and compassion, we’re developing therapies that aim to bring light back to lives touched by vision loss.

Vision loss changes more than how someone sees the world — it changes how they experience it. That’s why we’re committed to developing innovative therapies that do more than address conditions; they aim to bring light, connection, and independence back into people’s lives.

Learn more about our mission at https://kiorapharma.com/

12/23/2025

KIO-104 is an investigational therapy designed to target inﬂammation in the retina without relying on steroids or systemic drugs. It works by inhibiting DHODH, an enzyme critical for T-cell replication and function, which helps reduce damaging immune activity in the eye. Currently, it’s being studied in the Phase 2 KLARITY-1 trial for conditions like uveitis and diabetic macular edema.

Learn more about KIO-104 at https://kiorapharma.com/pipeline-science/kio-104/

12/17/2025

Witnessing the world come back into focus. That’s the power of possibility.

For participants in our KIO-301 clinical trials, moments like these reaffirm Kiora Pharamaceuticals’ purpose: to restore light, connection, and independence to those living with inherited retinal diseases.

Learn more about KIO-301 at https://kiorapharma.com/pipeline-science/kio-301/

12/11/2025

Moments like this remind us what vision restoration can mean in real life.

A participant in the KIO-301 clinical trial shared their experience after treatment. Every small step forward brings us closer to reimagining what’s possible for people living with inherited retinal diseases.

Learn more about KIO-301 and its potential impact on patients' lives: https://bit.ly/Kiora_Home

12/03/2025

Inflammation plays a central role in many retinal diseases, often leading to tissue damage and vision loss over time.

KIO-104 is a potent, locally delivered small molecule in development to address retinal inflammation. By targeting inflammation, KIO-104 aims to protect and improve vision in conditions such as posterior non-infectious uveitis, diabetic macular edema and other retinal inflammatory diseases.

The ongoing Phase 2 KLARITY study is evaluating the safety, tolerability, and efficacy of KIO-104 in patients with posterior non-infectious uveitis, diabetic macular edema, and other retinal inflammatory diseases.

Learn more about KIO-104 at https://kiorapharma.com/pipeline-science/kio-104/

11/25/2025

A new chapter is unfolding in retinal disease research. Laboratoires Théa announced progress across four retinal programs—including our joint work on KIO-301—moving us closer to therapies with meaningful impact.

At Kiora Pharmaceuticals, we’re driven by science, yet grounded in the lives of people and families affected by vision loss. This announcement highlights how far collaboration and purpose can take us.

📖 Learn more: https://thea.com/en_WW/news/thea-opens-a-new-chapter-in-retinal-diseases

11/20/2025

Kiora Pharmaceuticals is proud to join Global Genes’ RARE-X Vision Consortium as a founding member, partnering with leading advocacy groups and research organizations to accelerate the development of therapies for rare ocular diseases.

This collaboration helps create a centralized data resource and advancing new outcome measures that bring the patient voice to the forefront of clinical development. Together, we aim to make a meaningful impact for people living with inherited retinal diseases and other rare vision disorders.

🔗 Learn more about the RARE-X Vision Consortium and our commitment to improving vision for all at https://www.prnewswire.com/news-releases/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders-302599561.html?tc=eml_cleartime

11/12/2025

At Kiora Pharmaceuticals, we are dedicated to advancing therapies that have the potential to slow, stop, or restore lost vision. Our work is guided by science, but ultimately driven by the patients and families impacted by inherited retinal diseases.

These conditions can affect daily life in profound ways, and too often, treatment options are limited or unavailable. That’s why our team is committed to developing innovative, mutation-agnostic therapies designed to expand possibilities for patients—regardless of their genetic cause.

Every step forward in research brings us closer to a future where more people living with vision loss have access to meaningful treatment options.

Learn more about our mission at https://kiorapharma.com/

11/06/2025

KIO-104 is a potent, locally delivered small molecule in development to treat retinal inflammation.

By targeting the root cause of inflammation, KIO-104 aims to protect and improve vision in conditions such as posterior non-infectious uveitis, diabetic macular edema and other retinal inflammatory diseases.

🔗 Learn more about our pipeline at https://kiorapharma.com/pipeline-science/kio-104/

10/28/2025

Hear this inspiring story from one of Kiora Pharmaceuticals’ clinical trial participants, where she was delighted to be able to enjoy watching a bit of cricket on television. This everyday moment reflects the hope KIO-301 brings to those living with inherited retinal diseases.

Discover how KIO-301 is potentially revolutionizing vision restoration at https://bit.ly/Kiora_Home

Address

332 Encinitas Boulevard, Suite 102
Encinitas, CA
92024

Website

http://kiorapharma.com/

Alerts

Be the first to know and let us send you an email when Kiora Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Kiora Pharmaceuticals:

Shortcuts

Want your practice to be the top-listed Clinic in Encinitas?